![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Press Release: Online availability of Sanofi’s half-year financial report for 2024 Online availability of Sanofi’s half-year financial report for 2024 Paris, July 25, 2024. Sanofi announces that...
Communiqué de presse : Mise en ligne du rapport financier semestriel 2024 de Sanofi Mise en ligne du rapport financier semestriel 2024 de Sanofi Paris, le 25 juillet 2024. Sanofi annonce...
Sanofi Q2: strong performance with 10% sales growth; 2024 guidance upgraded Paris, July 25, 2024 Q2 sales growth of 10.2% at CER and business EPS(1) of €1.73 Dupixent sales up 29.2% to €3,303...
Communiqué de presse : Forte performance au deuxième trimestre soutenue par une croissance des ventes de 10% - Perspectives 2024 relevées Forte performance au deuxième trimestre...
Sanofi: Information concerning the total number of voting rights and shares – June 2024 Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8...
Sanofi: Informations relatives au nombre de droits de vote et d'actions – Juin 2024 Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L. 233-8 II du...
NEJM publishes ALTUVIIIO XTEND-Kids phase 3 data supporting its potential to transform the treatment landscape for children with severe hemophilia A ALTUVIIIO provides high-sustained factor...
Communiqué de presse : Le NEJM publie les données de phase III de l’étude XTEND-Kids montrant qu’ALTUVIIIO a le potentiel de transformer la prise en charge thérapeutique des enfants atteints...
Communiqué de presse : Dupixent devient le tout premier médicament ciblé pour le traitement de la BPCO approuvé dans l’Union européenne Dupixent devient le tout premier médicament ciblé pour...
Press Release: Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD...
Period † | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 4.66 | 5.05642361111 | 92.16 | 98.2 | 91.36 | 1587745 | 94.48481941 | DE |
4 | 6.59 | 7.30355757509 | 90.23 | 98.2 | 89.73 | 1348928 | 92.64312166 | DE |
12 | 4.99 | 5.43395404552 | 91.83 | 98.2 | 85.94 | 1465045 | 90.72904914 | DE |
26 | 5.15 | 5.61797752809 | 91.67 | 98.2 | 84.93 | 1439053 | 89.63297943 | DE |
52 | -0.73 | -0.748334187596 | 97.55 | 104.32 | 80.6 | 1463996 | 91.40821161 | DE |
156 | 8.93 | 10.1604278075 | 87.89 | 106.66 | 76.45 | 1783429 | 91.29116406 | DE |
260 | 20.95 | 27.6130222749 | 75.87 | 106.66 | 67.65 | 2004915 | 88.13460186 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions